Heart failure drug trial aims to boost stamina and brain power
NCT ID NCT07202000
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tests an experimental drug (activin ligand-trap) combined with exercise training in 48 adults with a common type of heart failure (HFpEF). The goal is to see if the drug can improve how much oxygen the body uses during exercise and also sharpen thinking skills. Participants will be randomly assigned to receive either the drug or a placebo, and results will be measured after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.